Promising Results for Drug for Depression Plus Insomnia

Source link :

Seltorexant, an investigational drug being developed by Johnson & Johnson, met all primary and secondary endpoints in a phase 3 trial of patients with major depressive disorder (MDD) with insomnia symptoms, the company has announced. Seltorexant is an investigational potential first-in-class selective antagonist of the human orexin 2 receptor being studied for the adjunctive treatment […]

Author : News Health

Publish date : 2024-05-30 09:04:42

Copyright for syndicated content belongs to the linked Source.